Pro-survival roles for p21(Cip1/Waf1) in non-small cell lung cancer
p21-dependent quiescence exists in TP53 wild-type NSCLC cells and provides survival advantages to these cells. Targeting p21 function in TP53 wild-type tumours could lead to better outcomes for chemotherapy treatment in NSCLC patients.
Authors
- Philipp Thomas (ORCID: https://orcid.org/0000-0003-4919-8452)
- Louise Fets (ORCID: https://orcid.org/0000-0002-0317-2540)
- Alexis R. Barr (ORCID: https://orcid.org/0000-0002-6684-8114)
- Sujal R. Desai (ORCID: https://orcid.org/0000-0002-5237-3613)
- P. Ortega-Prieto
- Maria Secrier (ORCID: https://orcid.org/0000-0003-2758-1741)
- SJ Cutty
- FA Hughes
Institutions
- Charing Cross Hospital (GB)
- MRC London Institute of Medical Sciences (GB)
- University College London (GB)
- Imperial College London (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1038/s41416-024-02928-9
- Citations
- 3
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Wellcome
- UK Research and Innovation
- Cancer Research UK
- National Institute for Health and Care Research
- Research Councils UK
- University of Oxford
- Medical Research Council
- Engineering and Physical Sciences Research Council
- Biotechnology and Biological Sciences Research Council
- NIHR Imperial Biomedical Research Centre